Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT00997334
Title Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors David M. Jackman, MD
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02115 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field